Search Results

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2023 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2023.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.

Sinovac Biotech Ltd. announced today that its Board of Directors (the “Board of Directors”) unanimously determined that the partial tender offer (the “Tender Offer”) by Alternative Liquidity Index LP (“Alternative Liquidity”).

Sinovac Biotech Ltd. announced that its Board of Directors unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for $0.03 per share in cash is NOT advisable and is NOT in the best interests of the Company or its shareholders.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced its unaudited financial results for the six months ended June 30, 2023.

With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and otherwise capitalizing on exit opportunities.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, confirmed that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced it will provide its inactivated COVID-19 vaccine, CoronaVac®, to self-paying groups in Hong Kong.

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Sinovac Biotech Ltd. announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.